Printer Friendly

NOVOPHARM LIMITED ACQUIRES GRANUTEC INC.

 TORONTO, July 6 /PRNewswire/ -- Novopharm Limited has completed the acquisition of its first U.S. based manufacturing facility, Granutec Inc. The agreement, signed on July 1, 1993 with Roussel Uclaf, leaves the current senior management at Granutec intact. While the terms of the agreement were not disclosed, Leslie Dan, chairman and CEO of Novopharm, notes that Granutec employees are extremely pleased with the overall plans.
 Granutec Inc. is a manufacturer of private label, over-the-counter (OTC) pharmaceuticals, with reported sales in 1992 of US$32 million and 1993 projections of more than US$40 million. The company has manufacturing facilities in Wilson, N.C., and packaging and distribution facilities in Largo, Fla.
 Plans are already under way for a major addition to the Wilson, N.C., facility and construction could start as early as October of this year. The expansion will result in the creation of between 50 and 75 new jobs as well as an investment of US$15 million.
 "The goal is to see the Wilson facility handling not only the manufacturing of Granutec's OTC products, but also the manufacturing of Novopharm's generic pharmaceuticals for sale in the United States in the newly constructed Novopharm plant," said Dan. The Wilson facility could begin manufacturing generic pharmaceuticals for Novopharm as early as 1994, pending approval by the Food and Drug Administration (FDA) for a site transfer.
 Novopharm Ltd. is a privately owned Canadian-based manufacturer of generic pharmaceuticals. Novopharm has held the number one position in terms of prescriptions dispensed for over 5 years running.
 The Novopharm group of companies is comprised of four divisions: Novopharm Ltd., a generic manufacturer with distribution across Canada, the United States, through Novopharm USA, in Europe, Central America, the Pacific Rim, and the Middle East; private label division consisting of Stanley Pharmaceuticals, Vancouver, B.C. and Granutec Inc., Wilson, N.C.; Novopharm Biotech, engaged in innovative research in the field of cancer treatment; and Eldan Pharmaceuticals, an innovative pharmaceutical company introducing new pharmaceuticals through licensing agreements.
 -0- 7/06/93
 /CONTACT: Andrea Dan, communications officer of Novopharm Ltd., 416-291-8876 or fax, 416-291-2162/


CO: Novopharm Limited; Granutec Inc. ST: Ontario, North Carolina, Florida IN: MTC SU: TNM

MP -- NY029 -- 8591 07/06/93 11:41 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 6, 1993
Words:370
Previous Article:CASH AMERICA COMPLETES $125 MILLION REVOLVING BANK LINE
Next Article:PIERRE SALINGER JOINS GLOBAL TELEWORKS BOARD OF DIRECTORS
Topics:


Related Articles
NOVOPHARM LTD. TO ACQUIRE GRANUTEC INC.
NOVOPHARM LTD. TO ACQUIRE GRANUTEC INC.
DEPRENYL RESEARCH LIMITED AND NOVOPHARM LIMITED ANNOUNCE STRATEGIC ALLIANCE
NOVOPHARM BREAKS GROUND ON $38 MILLION PHARMACEUTICAL PLANT IN NORTH CAROLINA
AMERICAN HOME PRODUCTS WYETH-AYERST INTERNATIONAL SUBSIDIARY SIGNS MARKETING AGREEMENT WITH NOVOPHARM
WARRICK PHARMACEUTICALS AND NOVOPHARM USA EXTEND AGREEMENT ON GENERIC DRUG PRODUCTS
NOVOPHARM WINS RIGHT TO MAKE GLAXO WELLCOME'S ZANTAC; RULING ENDS SIX-YEAR BATTLE WITH DRUG GIANT TO MAKE GENERIC ZANTAC
COURT RULES IN ZANTAC PATIENT INFRINGEMENT ACTION
U.S. Appeals Court Clears Final Hurdle for Novopharm to Make Glaxo Wellcome's Zantac
Leiner Health Products Acquires Assets of Granutec, Inc.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters